TMTosti J. Mankelow

Tosti J. Mankelow

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tosti J. Mankelow has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of a novel high‐prevalence red blood cell antigen on junctional adhesion molecule‐ A defines a new blood group system

    by Tosti J. Mankelow, Louise A. Tilley, Vanja Karamatic Crew, Benjamin Jones, Marina Izak, Liora Muncher, Vered Yahalom, Nicole M. Thornton

    Background and Objectives: Availability of new technologies has accelerated the pace of blood group discovery, with nine of 48 known systems being discovered in the past 5 years alone, and yet uncharacterized antigens remain. This study involved investigations of samples from a female patient presenting with a moderate strength pan‐reactive antibody to a high‐prevalence antigen present on all red blood cells (RBCs) tested other than her own and her brother's. Materials and Methods: Samples underwent extensive serological testing; however, the antibody specificity could not be assigned to any known blood group antigens. Therefore, whole exome sequencing was performed alongside antigen expression studies to identify the gene variant responsible for this rare phenotype. Results: Both individuals were found to carry a homozygous variant c.644G>A (rs755819660; gnomAD allele frequency 0.0000044) in exon 6 of the F11R gene, encoding junctional adhesion molecule‐A (JAM‐A). This variant encodes p.Arg215Gln located on the second extracellular immunoglobulin domain of JAM‐A. Expression of JAM‐A was demonstrated on all RBCs tested by flow cytometry, with cells of both the patient and her brother showing lower expression than control cells. Control (Arg215) and variant (Gln215) forms of JAM‐A were expressed as both soluble Fc fusion proteins and on Chinese hamster ovary cells. In both cases, mouse monoclonal anti‐JAM‐A recognized both forms, whilst the patient antibody only reacted with the Arg‐215‐JAM‐A control. Conclusion: These data demonstrate that JAM‐A carries a new high‐prevalence RBC antigen, lacking in the patient and her brother, thereby defining a novel blood group system encoded by F11R .

  • Deletions in the MAL gene result in loss of Mal protein, defining the rare inherited AnWj-negative blood group phenotype

    by Louise A. Tilley, Vanja Karamatic Crew, Tosti J. Mankelow, Samah A. AlSubhi, Benjamin Jones, Abigail Borowski, Vered Yahalom, Lilach Finkel, Belinda K. Singleton, Piers J. Walser, et al.

    The genetic background of the high prevalence red blood cell antigen AnWj has remained unresolved since its identification in 1972, despite reported associations with both CD44 and Smyd1 histone methyltransferase. Development of anti-AnWj, which may be clinically significant, is usually due to transient suppression of antigen expression, but a small number of individuals with persistent, autosomally recessive inherited AnWj-negative phenotype have been reported. Whole-exome sequencing of individuals with the rare inherited AnWj-negative phenotype revealed no shared mutations in CD44H or SMYD1; instead, we discovered homozygosity for the same large exonic deletion in MAL, which was confirmed in additional unrelated AnWj-negative individuals. MAL encodes an integral multipass membrane proteolipid, myelin and lymphocyte protein (Mal), which has been reported to have essential roles in cell transport and membrane stability. AnWj-positive individuals were shown to express full-length Mal on their red cell membranes, which was not present on the membranes of AnWj-negative individuals, regardless of whether from an inherited or suppression background. Furthermore, binding of anti-AnWj was able to inhibit binding of anti-Mal to AnWj-positive red cells, demonstrating the antibodies bind to the same molecule. Overexpression of Mal in an erythroid cell line resulted in the expression of AnWj antigen, regardless of the presence or absence of CD44, demonstrating that Mal is both necessary and sufficient for AnWj expression. Our data resolve the genetic background of the inherited AnWj-negative phenotype, forming the basis of a new blood group system, further reducing the number of remaining unsolved blood group antigens.


  • Open Access

    Blood group type A secretors are associated with a higher risk of COVID‐19 cardiovascular disease complications

    by Tosti J. Mankelow, Belinda K. Singleton, Pedro L. Moura, Christian J. Stevens‐Hernandez, Nicola M. Cogan, Gyongyver Gyorffy, Sabine Kupzig, Luned Nichols, Claire Asby, Jennifer Pooley, et al.

    The SARS‐CoV‐2 virus causes COVID‐19, an infection capable of causing severe disease and death but which can also be asymptomatic or oligosymptomatic. We investigated whether ABO blood group or secretor status was associated with COVID‐19 severity. We investigated secretor status because expression of ABO glycans on secreted proteins and non‐erythroid cells are controlled by a fucosyltransferase (FUT2), and inactivating FUT2 mutations result in a non‐secretor phenotype which protects against some viral infections. Data combined from healthcare records and our own laboratory tests (n = 275) of hospitalized SARS‐CoV‐2 polymerase chain reaction positive patients confirmed higher than expected numbers of blood group A individuals compared to O (RR = 1.24, CI 95% [1.05, 1.47], p = 0.0111). There was also a significant association between group A and COVID‐19‐related cardiovascular complications (RR = 2.56, CI 95% [1.43, 4.55], p = 0.0011) which is independent of gender. Molecular analysis revealed that group A non‐secretors are significantly less likely to be hospitalized than secretors. Testing of convalescent plasma donors, among whom the majority displayed COVID‐19 symptoms and only a small minority required hospitalization, group A non‐secretors were slightly over‐represented. Our findings showed that group A non‐secretors are not resistant to infection by SARS‐CoV‐2, but are more likely to experience a less severe form of associated disease.


  • Open Access

    Non-muscle myosin II drives vesicle loss during human reticulocyte maturation

    by Pedro L. Moura, Bethan R. Hawley, Tosti J. Mankelow, Rebecca E. Griffiths, Johannes G.G. Dobbe, Geert J. Streekstra, David J. Anstee, Timothy J. Satchwell, Ashley M. Toye

    The process of maturation of reticulocytes into fully mature erythrocytes that occurs in the circulation is known to be characterized by a complex interplay between loss of cell surface area and volume, removal of remnant cell organelles and redundant proteins, and highly selective membrane and cytoskeletal remodeling. However, the mechanisms that underlie and drive these maturational processes in vivo are currently poorly understood and, at present, reticulocytes derived through in vitro culture fail to undergo the final transition to erythrocytes. Here, we used high-throughput proteomic methods to highlight differences between erythrocytes, cultured reticulocytes and endogenous reticulocytes. We identify a cytoskeletal protein, non-muscle myosin IIA (NMIIA) whose abundance and phosphorylation status differs between reticulocytes and erythrocytes and localized it in the proximity of autophagosomal vesicles. An ex vivo circulation system was developed to simulate the mechanical shear component of circulation and demonstrated that mechanical stimulus is necessary, but insufficient for reticulocyte maturation. Using this system in concurrence with non-muscle myosin II inhibition, we demonstrate the involvement of non-muscle myosin IIA in reticulocyte remodeling and propose a previously undescribed mechanism of shear stress-responsive vesicle clearance that is crucial for reticulocyte maturation.


  • Open Access

    The ins and outs of reticulocyte maturation revisited: The role of autophagy in sickle cell disease

    by Tosti J. Mankelow, Rebecca E. Griffiths, Sara Trompeter, Joanna F. Flatt, Nicola M. Cogan, Edwin J. Massey, David J. Anstee

    Autophagy plays an important role in the removal of membrane bound organelles during the last stage of erythropoiesis as the enucleate reticulocyte matures into the erythrocyte. Autophagic vesicles are expelled from the reticulocyte as intact, inside-out, phosphatidylserine (PS) decorated vesicles and are subsequently removed during splenic passage. Failure to remove these vesicles causes the elevation in PS exposed red cells in Sickle Cell Disease.


  • Autophagic vesicles on mature human reticulocytes explain phosphatidylserine-positive red cells in sickle cell disease

    by Tosti J. Mankelow, Rebecca E. Griffiths, Sara Trompeter, Joanna F. Flatt, Nicola M. Cogan, Edwin J. Massey, David J. Anstee

    During maturation to an erythrocyte, a reticulocyte must eliminate any residual organelles and reduce its surface area and volume. Here we show this involves a novel process whereby large, intact, inside-out phosphatidylserine (PS)-exposed autophagic vesicles are extruded. Cell surface PS is a well-characterized apoptotic signal initiating phagocytosis. In peripheral blood from patients after splenectomy or in patients with sickle cell disease (SCD), the number of circulating red cells exposing PS on their surface is elevated. We show that in these patients PS is present on the cell surface of red cells in large (∼1.4 µm) discrete areas corresponding to autophagic vesicles. The autophagic vesicles found on reticulocytes are identical to those observed on red cells from splenectomized individuals and patients with SCD. Our data suggest the increased thrombotic risk associated with splenectomy, and patients with hemoglobinopathies is a possible consequence of increased levels of circulating mature reticulocytes expressing inside-out PS-exposed autophagic vesicles because of asplenia. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points Reticulocyte maturation involves the release of intact, inside-out autophagic vesicles with PS exposed on their surface. Elevated levels of autophagic vesicles on circulating reticulocytes cause PS exposure in patients with SCD.


  • Open Access

    Tetraspanins CD81 and CD82 Facilitate α4β1-Mediated Adhesion of Human Erythroblasts to Vascular Cell Adhesion Molecule-1

    by Frances A. Spring, Rebecca E. Griffiths, Tosti J. Mankelow, Christopher Agnew, Stephen F. Parsons, Joel A. Chasis, David J. Anstee

    The proliferation and terminal differentiation of erythroid progenitors occurs in human bone marrow within erythroblastic islands, specialised structures consisting of a central macrophage surrounded by developing erythroid cells. Many cell-cell and cell-matrix adhesive interactions maintain and regulate the co-ordinated daily production of reticulocytes. Erythroid cells express only one integrin, α4β1, throughout differentiation, and its interactions with both macrophage Vascular Cell Adhesion Molecule-1 and with extracellular matrix fibronectin are critical for erythropoiesis. We observed that proerythroblasts expressed a broad tetraspanin phenotype, and investigated whether any tetraspanin could modulate integrin function. A specific association between α4β1 and CD81, CD82 and CD151 was demonstrated by confocal microscopy and co-immune precipitation. We observed that antibodies to CD81 and CD82 augmented adhesion of proerythroblasts to Vascular Cell Adhesion Molecule-1 but not to the fibronectin spliceoforms FnIII 12-IIICS-15 and FnIII 12–15 . In contrast, different anti-CD151 antibodies augmented or inhibited adhesion of proerythroblasts to Vascular Cell Adhesion Molecule-1 and the fibronectin spliceoform FnIII 12-IIICS-15 but not to FnIII 12–15 . These results strongly suggest that tetraspanins have a functional role in terminal erythropoiesis by modulating interactions of erythroblast α4β1 with both macrophages and extracellular matrix.


  • The ins and outs of human reticulocyte maturation

    by Rebecca E. Griffiths, Sabine Kupzig, Nicola Cogan, Tosti J. Mankelow, Virginie M.S. Betin, Kongtana Trakarnsanga, Edwin J. Massey, Stephen F. Parsons, David J. Anstee, Jon D. Lane

    The maturation of reticulocytes into functional erythrocytes is a complex process requiring extensive cytoplasmic and plasma membrane remodeling, cytoskeletal rearrangements and changes to cellular architecture. Autophagy is implicated in the sequential removal of erythroid organelles during erythropoiesis, although how this is regulated during late stages of erythroid differentiation, and the potential contribution of autophagy during reticulocyte maturation, remain unclear. Using an optimized ex vivo differentiation system for human erythropoiesis, we have observed that maturing reticulocytes are characterized by the presence of one or few large vacuolar compartments. These label strongly for glycophorin A (GYPA/GPA) which is internalized from the plasma membrane; however, they also contain organellar remnants (ER, Golgi, mitochondria) and stain strongly for LC3, suggesting that they are endocytic/autophagic hybrid structures. Interestingly, we observed the release of these vacuoles by exocytosis in maturing reticulocytes, and speculate that autophagy is needed to concentrate the final remnants of the reticulocyte endomembrane system in autophagosome/endosome hybrid compartments that are primed to undergo exocytosis.


  • Maturing reticulocytes internalize plasma membrane in glycophorin A–containing vesicles that fuse with autophagosomes before exocytosis

    by Rebecca E. Griffiths, Sabine Kupzig, Nicola Cogan, Tosti J. Mankelow, Virginie M. S. Betin, Kongtana Trakarnsanga, Edwin J. Massey, Jon D. Lane, Stephen F. Parsons, David J. Anstee

    The erythrocyte is one of the best characterized human cells. However, studies of the process whereby human reticulocytes mature to erythrocytes have been hampered by the difficulty of obtaining sufficient numbers of cells for analysis. In the present study, we describe an in vitro culture system producing milliliter quantities of functional mature human adult reticulocytes from peripheral blood CD34+ cells. We show that the final stage of reticulocyte maturation occurs by a previously undescribed mechanism in which large glycophorin A–containing vesicles forming at the cytosolic face of the plasma membrane are internalized and fuse with autophagosomes before expulsion of the autophagosomal contents by exocytosis. Early reticulocyte maturation is characterized by the selective elimination of unwanted plasma membrane proteins (CD71, CD98, and β1 integrin) through the endosome-exosome pathway. In contrast, late maturation is characterized by the generation of large glycophorin A–decorated vesicles of autophagic origin.